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Blood pressureCortisol and aldosterone have the same in vitro afﬁnity for the mineralocorticoid receptor (MR), although in
vivo only aldosterone acts as a physiologic agonist of the MR, despite circulating levels of cortisol in humans
and corticosterone in rodents being three orders of magnitude higher than aldosterone levels. In
mineralocorticoid target organs the enzyme 11β-hydroxysteroid dehydrogenase type 2 (11βHSD2)
inactivates 11-hydroxy steroids, to their inactive keto-forms, thus protecting the nonselective MR from
activation by glucocorticoids. The gene is highly expressed in all sodium-transporting epithelia, particularly
in the kidney and colon, but also in human placenta and vascular wall. Mutations in the HSD11B2 gene cause
a rare monogenic juvenile hypertensive syndrome called apparent mineralocorticoid excess (AME). In AME,
compromised 11βHSD2 enzyme activity results in activation of the MR by cortisol, causing sodium retention,
hypokalaemia, and salt-dependent hypertension. Whereas mutations or inhibition of 11βHSD2 by licorice
have been clearly shown to produce a congenital or acquired syndrome of mineralocorticoid excess, the
questions remaining are the extent to which subtle abnormalities in MR/11βHSD2 mechanisms may
contribute to essential hypertension. Studies in patients with essential hypertension showed a prolonged
half-life of cortisol and an increased ratio of urinary cortisol to cortisone metabolites, suggesting a deﬁcient
11βHSD2 activity. These abnormalities may be genetically determined, as suggested by the association of a
microsatellite ﬂanking the HSD11B2 gene with hypertension in black patients with end-stage kidney disease
and with salt sensitivity of blood pressure in healthy subjects. These ﬁndings indicate that variants of the
HSD11B2 gene may contribute to the enhanced blood pressure response to salt and possibly to hypertension
in humans.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
In 1974 Werder et al. [1] described a case of a 3-year-old girl with
short stature, polydipsia and polyuria without obvious external
abnormalities (including genitalia), and who had features of miner-
alocorticoid hypertension with hypokalemia, metabolic alkalosis, and
suppressed plasma renin and aldosterone. Gas-chromatographic
analysis of her urinary steroid proﬁle excluded hypertensive forms
of congenital adrenal hyperplasia, but showed an unexpected steroid
proﬁle that the authors reported, but failed to recognise its relevance
[1]. Translumbar retroperitoneal carbon dioxide insufﬂation, a
technique for adrenal imaging available at that time [2], revealed no
enlargement of the patient's adrenal. Subsequently the patient
withdrew from further medical evaluation and management, her
whereabouts remained unknown until 25 years later, when she
presented with intracranial haemorrhage and ESKD [3]. Genetic
analysis demonstrated a compound heterozygosity with two muta-
tions in the gene encoding the enzyme 11β-hydroxysteroid dehydro-
genase type 2 (11βHSD2) [3], an enzyme which plays a crucial role inll rights reserved.mineralocorticoid regulated renal sodium transport. The underlying
defect affecting this girl was a condition that was characterized in the
late 1970s by Ulick and New and that was dubbed apparent
mineralocorticoid excess (AME) syndrome [4,5], because it mimicked
mineralocorticoid excess, but was not caused by a steroid with
mineralocorticoid action such as aldosterone or deoxycorticosterone.
It is now clear that AME is caused by mutations in the gene encoding
the enzyme 11βHSD2. In this overview we discuss the subsequent
cloning, physiology, pathophysiology, and clinical relevance of the
11β-hydroxysteroid dehydrogenase (11βHSD) enzymes.
2. Unmasking a new biological principle
The biochemical characterisation of the severe juvenile low-renin
hypertension termed apparent mineralocorticoid excess (AME) by
New et al. [4,5] unveiled a new biological principle. The classical view
of hormone action in target organs is that of hormone signalling by the
binding of ligand to a speciﬁc, cognate receptor. However, in
mineralocorticoid target organs, hormonal speciﬁcity is determined
by an enzyme and not the receptor.
When aldosterone enters the cell, it binds to the mineralocorticoid
receptor (MR), and thereafter the ligand-receptor complex is
translocated into the nucleus. Binding to hormone response elements
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aldosterone-inducible proteins, such as rate-limiting subunits of the
apical epithelial sodium channel (ENaC) (Fig. 1A). In response
sodium inﬂux causes intracellular sodium (Na+) to rise; this increase
in substrate increases turnover of Na+/K+ ATPase, which in turn
increases Na+ reabsorption and potassium (K+) excretion. Activation
and induction of these Na+ transporters is crucial to unfold the
physiological role of the aldosterone system, which is to counteract
excessive water and salt loss and maintain normotension in the face
ﬂuid losses. On the other hand, unrestrained activation of the MR, as
occurs in many forms of mineralocorticoid hypertension, causes
excessive Na+ reabsorption leading to volume expansion and
contributes to hypertension.Fig. 1. Mineralocorticoid action in renal cells of the cortical collecting duct (CCD): (A) Whe
thereafter the ligand-receptor complex is translocated into the nucleus. Binding to its hor
aldosterone-inducible proteins, such as the rate-limiting subunits of the apical epithelial sodi
(Na+) reabsorption and potassium (K+) excretion. (B)When cortisol enters the CCD cell the
it to inactive cortisone and generates high levels of NADH, thereby protecting the MR by fr
inherited or acquired reduction in enzymatic activity, the intracellular cortisol level increases
resulting glucocorticoid activation of MR produces Na+ retention, volume expansion and hIn vitro binding studies demonstrate that cortisol and aldosterone
have the same afﬁnity for MR, although in mineralocorticoid target
organs only aldosterone acts as the physiologic agonist (Fig. 1B) [6].
The MR is protected from activation by glucocorticoids through the
agency of a gatekeeper enzyme, the microsomal 11β-hydroxysteroid
dehydrogenase type 2 enzyme (11βHSD2), evidence that mineralo-
corticoid target tissue speciﬁcity is enzyme, not receptor, mediated
(Figs. 1 and 2) [7]. MR and glucocorticoid receptors (GR) have a high
degree of sequence identity [8], 94% in the central DNA-binding
domain and 57% in the C-terminal ligand-binding domain. With the
cloning and expression of theMR [8] it was conﬁrmed that aldosterone
and cortisol have similar binding afﬁnities for MR in vitro [9,10].
Circulating levels of cortisol in humans and corticosterone in rodentsn aldosterone enters the CCD cell, it binds to the mineralocorticoid receptor (MR), and
mone response element (HRE) increases the transcription of genes encoding speciﬁc
um channel (ENaC), sgk-1 and basolateral Na/K-ATPase. In turn, this stimulates sodium
enzyme 11β-hydroxysteroid dehydrogenase type 2 (11βHSD2) largely (∼90%) converts
om activation by cortisol. C. When 11βHSD2 activity is decreased as a consequence of
further, but the level of NADH plummets, leading to activation of theMR by cortisol. The
ypertension.
Fig. 2. Peripheral cortisol metabolism and mineralocorticoid receptor selectivity:
cortisol and aldosterone bind with equal afﬁnity to the mineralocorticoid receptor
(MR). Plasma concentrations of cortisol are 1000× higher than those of aldosterone, but
in MR-target cells the NAD-dependent 11β-hydroxysteroid dehydrogenase type 2
(11βHSD2) debulks intracellular cortisol and generates high levels of NADH. Generated
NADHmaintains cortisol–MR complexes in an inactive state and permits aldosterone to
selectively activate the receptor, despite 10× higher intracellular cortisol levels. The
hemiacetal conformation of the 11-hydroxyl group with the 18-aldehyde group of
aldosterone renders this steroid a poor substrate for the enzyme. Cortisol and cortisone
are substrates for a series of enzymatic activities in the liver. These include reduction of
Δ4 double bond yielding 5α- and 5β-dihydrocortisol (DHF) and dihydrocortisone
(DHE), and reduction of 3-keto group, producing 5α- and 5β-tetrahydrocortisol (THF)
and tetrahydrocortisone (THE). The activity of the 11βHSD2 enzyme can be assessed in
vivo by measuring the urinary (THF+5αTHF)/THE ratio by gas chromatography and
mass spectrometry. In normal subjects this ratio ranges between 0.7 and 1.5.
Table 1
11β-hydroxysteroid dehydrogenase (11βHSD) isoenzymes.





30 kb, 6 exons 6.2 kb, 5 exons
mRNA 1902 bases 1944 bases
Amino acids 292, 34 kDa 405, 45 kDa
Enzyme kinetics
Activity bi-directional, reductase in vivo dehydrogenase only
Substrate
afﬁnity







ubiquitous, mainly liver, lung kidney, colon, sweat
glands





Function elevation of cellular cortisol
concentration
protection of the MR
MR=mineralocorticoid receptor.
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which in vivo only aldosterone acts as a physiologic agonist of the MR.
This paradox was apparently solved by the discovery of the enzyme
11βHSD [7,10], which converts biologically active 11-hydroxysteroids
to their inactive 11-keto-steroid forms, thus conferring ligand
speciﬁcity on MR; in addition, it stoichometrically generates NADH,
which appears to be crucial in maintaining glucocorticoid-occupied
MR in an inactive state, bymechanismswhich remain to be established
[11]. Cyclisation of the 11-hydroxyl groupwith the 18-aldehyde group
of aldosterone renders the physiological mineralocorticoid resistant to
11βHSD. Of the two cloned 11βHSD isoforms, only the type 2
(11βHSD2) acts in this way to protect MR. When 11βHSD2 activity
is decreased, reﬂecting inhibition or mutation, cortisol is able to
stimulate MR and induces the state of apparent mineralocorticoid
excess (Fig. 1C).
3. 11βHSD cloning, tissue localization and biochemistry
The 11βHSD enzymes catalyse the interconversion of cortisol and
cortisone in humans (Fig. 2), and of corticosterone and dehydrocorti-
costerone in rodents [7]. Cortisone and dehydrocorticosterone show
minimal biological activity per se, reﬂecting their negligible afﬁnity for
GR and MR. Two kinetically distinct forms of 11βHSD (11βHSD1 und
11βHSD2) have been cloned and are differentiated by directionality
in vivo, cofactor speciﬁcity and tissue expression (Table 1) [12–16].
11βHSD1 activity and expression is found in most tissues; its Km for
cortisol is more than an order of magnitude higher than that of
11βHSD2; it is reduced nicotinamide adenine dinucleotide phosphate
(NADPH)-preferring, and has been shown to have overwhelminglyreductase activity in vivo (Table 1).Mice lacking11βHSD1have elevated
circulating levels of plasma corticosterone and show reduced glucocor-
ticoid responses including blunted gluconeogenesis in response to
fasting, and improved lipid proﬁles, but no hypertension. [17–19].
In contrast, 11βHSD2 has been identiﬁed in a limited range of
tissues primarily involved in transepithelial sodium transport
[14–16]. It has a low Km for cortisol (40–50 nM), and even lower for
corticosterone (∼4 nM), is nicotinamide adenine dinucleotide (NAD)-
requiring and shows only dehydrogenase activity for endogenous
glucocorticoids (Fig. 2, Table 1) [14–16], although reduction of
dehydrodexamethasone has been demonstrated in vitro [20,21].
Immunohistochemical studies have consistently localized
11βHSD2 to a restricted range of organs, primarily expressing
sodium-transporting epithelia such as distal renal tubules, distal
colon, sweat and salivary glands, but also placenta and vascular wall
[14–16,22,23]. Odermatt et al. [24] co-expressed epitope-tagged MR
and 11βHSD2 in HEK-293 cells lacking 11βHSD2 activity and analysed
their subcellular localization by ﬂuorescence microscopy. When co-
expressed with 11βHSD2 the MR displayed a reticular distribution
pattern, absent ligand, suggesting association of MR with 11βHSD2 at
the endoplasmic reticulum membrane. Aldosterone induced rapid
nuclear translocation of MR, with the enzyme remaining tethered in
the cytoplasmic compartment. In parallel studies [25], green ﬂuores-
cent protein (GFP) tagged MR were expressed in similar cells, and
absent steroid MR were similarly shown to be predominantly
cytoplasmic. Addition of aldosterone, corticosterone or spironolac-
tone all served to move MR intranuclear—rapidly with aldosterone,
less rapidly with corticosterone, slowly and only partially with
spironolactone [25].
11βHSD2 in the kidney is primarily expressed in the cells of the
cortical collecting duct [23,26,27]; in contrast, the liver is the principal
site for cortisone to cortisol conversion by 11β-hydroxysteroid
dehydrogenase type 1 (11βHSD1). Both cortisol and cortisone are
substrates for a series of enzymatic activities in the liver, including the
reduction of Δ4 double bond to reduction of 3-keto group and
reduction of 20-keto group, most of whichmetabolites are excreted in
the urine as glucuronides, with only a small part excreted unconju-
gated, mainly as 3-oxo-4-ene steroids [28]. The activity of the
11βHSD2 enzyme can be reliably assessed in vivo by measuring the
ratio of biologically active cortisol (F) to inactive cortisone (E), or their
tetrahydrometabolites (THF and THE), in the urine by gas chroma-
tography with mass spectrometry [29,30]. Increase in urinary free F/E
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11βHSD2 activity [31].
4. Adrenal steroids, renal salt handling and blood
pressure regulation
4.1. Aldosterone, blood pressure and salt
Normal regulation of ﬂuid and electrolyte homeostasis in
mammals is regulated in a negative-feedback loop by the renin–
angiotensin–aldosterone system [32], and by the direct effects of
plasma [K+] on aldosterone secretion [33]. Renin is released by the
juxtaglomerular cells of the afferent arterioles and macula densa cells
of the kidney, and aldosterone is produced by the adrenal glands.
Plasma concentrations of renin and angiotensin II rise in response to
contraction of intravascular volume and reduction in renal perfusion,
and are lowered by intravascular volume expansion. To maintain
blood pressure and organ perfusion healthy subjects respond to
volume loss by an increase in renin and aldosterone secretion, which
minimises urinary Na+ losses and enhances water retention, and
respond to K+ loading by a direct effect on the adrenal to raise
aldosterone secretion rate and thus K+ excretion. Complex organisms
on the planet evolved in the Na+-rich aqueous environment of the sea
[34], and terrestrial life thus necessitated the development of
mechanisms to retain Na+ [35]. Fractional regulation of salt and
water balance involves the kidney [36,37], and in particular the renal
medulla, which develops very differently between species, and is
more prominent in species with a high urinary concentrating capacity
[38]. Nephron elements such as the loop of Henle and the collecting
duct, which function to concentrate the urine by increasing Na+ and
water reabsorption, are found in humans and other terrestrial
mammals, but are absent or rudimentarily developed in ﬁsh and
amphibians. This evolutionary adaptation of the nephron underlines
the central role of the kidney in the homeostatic regulation of Na+ and
water balance [35].
Most species, including humans, evolved in a Na+ poor, K+ rich
context [36,37], and thus needed to retain as much dietary salt as
possible, and conversely to shed potassium. It has been estimated that
in the ﬁrst 10 million years of existence, as hunters and gatherers,
humans enjoyed a dietary salt intake of approximately 1 g daily
(∼17 meq). Given the variable availability of salt, particularly inland,
humans developed regulatory mechanisms to prevent loss of Na+
through the kidney and other epithelia, in which aldosterone, MR and
11βHSD2 are crucial elements. It is important to note that MR
preceded terrestrial evolution and are clearly present in ﬁsh, which
lack the capacity tomake aldosterone. Cortisol is thus the evolutionary
driver for MR [39]; a possibly useful question might thus be why
epithelial Na+/K+ balance regulation pressed into service an existing
receptor, which recognised a ‘novel’ ligand (aldosterone) with afﬁnity
equivalent to that for cortisol, protected in epithelia by the co-
expression of 11βHSD2 at very high levels, rather than evolving an
aldosterone-speciﬁcMR. Species that are able to transport ormine salt,
or balance Na+ and K+ intake by meat eating, appear unable to
suppress aldosterone to a degree sufﬁcient to obviate a pattern of
deleterious effects seen experimentally magniﬁed in animals admin-
istered exogenous aldosterone and maintained on 0.9% NaCl solution
to drink [40]. This possible inability to lower aldosterone appropriately
in the face of a normal (Western) Na+ intake (150–500 meq/day),
coupled with an unrestricted Na+ appetite, may thus be a major
contributing factor to human cardiovascular disease [41].
4.2. Cortisol and blood pressure
Glucocorticoid (GC) treatment and endogenous cortisol excess as
seen in Cushing's syndrome have a profound effect on blood pressure
[42]. The exact mechanisms mediating cortisol-induced hypertensionare still not fully understood. The pathogenesis of hypertension in
Cushing's syndrome is multifactorial and may involve the following
factors: (a) the activation of the MR by cortisol excess in the distal
kidney tubule, leading to excess sodium Na+ retention; (b) an
enhanced hepatic production of angiotensinogen, providing increased
abundance of renin substrate [43,44]; and (c) an increased peripheral
vascular sensitivity to adrenergic agonists [45]. It is obvious that
excess renal sodium Na+ retention and the ensuing increase in blood
volume characterize the primary mechanism for GC-associated
hypertension. This is the consequence of excess MR stimulation by
supra-physiologic cortisol concentration and the failure of the enzyme
11βHSD2 fails to adequately convert cortisol into the inactive form
cortisone because substrate availability is greater than the rate of
conversion to its product. Kinetic properties of 11βHSD2 suggest that
saturability of this enzyme can already be achieved at high-normal
physiologic plasma cortisol levels [20,46]. As a result, stimulation of
the MR by cortisol leads to renal Na+ retention, volume expansion
and ﬁnally to an increase in blood pressure with suppression of renin
secretion. In patients with pituitary and particularly with ectopic
Cushing's syndrome, defective 11βHSD2 activity can be demonstrated
by an increased urinary cortisol to cortisone ratio [29,47]. Correction
of hypertension by kidney transplantation in a patient with AME [48]
argues in favour of a central role of the kidney in the pathogenesis of
GC-associated hypertension related to 11βHSD2 deﬁciency.
However, some observations suggest that mechanisms indepen-
dent from Na+ retention play an important role in glucocorticoid-
associated hypertension. It has been shown that the Na+ retention
and increase in blood pressure induced by exogenous cortisol may not
be fully reversed by spironolactone [49,50]. Since spironolactone acts
by competitive inhibition of binding to MR [51], it is possible that the
doses of cortisol given in these studies [49,50] were sufﬁciently high
to produce circulating levels that compete with spironolactone for
MR. Nevertheless, other renal or extrarenal effects of cortisol upon GR
have to be considered. There is good evidence that exogenous cortisol
potentiates vasopressor responses to angiotensin II and catechola-
mines [52] and recent studies have shown that corticosterone
enhances phenylephrine-induced contraction of intact aortic rings
via induction of mitogen-activated protein kinases [53]. There is also
evidence implicating the MR in the central nervous system in the
pathogenesis of mineralocorticoid hypertension [54,55]. In animal
experiments, intracerebroventricular administration of very low
doses of aldosterone can induce hypertension and this effect can be
progressively blocked by 1- to 2-fold ICV corticosterone [56], thus
suggesting that there may be no pathophysiological role for 11βHSD.
Thus, future investigations in this ﬁeld will need to take into account a
wider spectrum of mechanisms including vasoconstriction and
angiotensin II response.
5. 11βHSD2 and mineralocorticoid hypertension
A markedly reduced activity of 11βHSD2 can be caused by
mutations in the HSD11B2 gene or inhibition of this enzyme by
xenobiotics such as licorice. The clinical syndromes ensuing from
HSD11B2 gene mutations or inhibition of 11βHSD2 by exogenous
compounds are indistinguishable and present as mineralocorticoid
hypertension with hypokalaemia, metabolic alkalosis and suppressed
circulating renin and aldosterone. Hypertension is primarily caused by
sodium and ﬂuid retention secondary to excess activation of the MR
by cortisol.
5.1. Apparent mineralocorticoid excess (AME)
Inherited deﬁciency in 11βHSD2 causing impaired peripheral
metabolism of cortisol and presenting with juvenile hypokalaemic
hypertension is known as the syndrome of apparent mineralocorti-
coid excess (AME) [1,4,5]. Typical clinical signs and symptoms of AME
Fig. 3. Location of HSD11B2 gene mutations: The HSD11B2 gene is located on chromosome 16 and consists of 5 exons, labelled I through V (grey boxes). Introns are represented by
the lines and the untranslated regions by the open boxes. Numbers below the exons indicate the amino acid (AA) number. Mutations are listed relative to their position in the gene.
Those shown below the gene are mutations investigated by the author, with mutations reported above the gene reported by others.
Fig. 4. Genotype–phenotype correlations in apparent mineralocorticoid excess (AME):
The bars show the results of in vitro enzymatic activity assays using CHOP cells
transfected with mutant plasmids of the 11β-hydroxysteroid dehydrogenase type 2
(HSD11B2) gene. Transfected cells were incubated for 2 hours with [3H]-cortisol, with
[3H]-cortisol and [3H]-cortisone from the supernatant at the end of incubation
separated by chromatography and quantiﬁed. Birth weight, blood pressure, serum
potassium and the urinary (THF+5αTHF)/THE ratio as a measure of in vivo 11βHSD2
activity are correlated with the genotype and in vitro 11βHSD2 activity. When in vitro
enzymatic activity is completely abolished as a consequence of mutations in the
HSD11B2 gene carriers of the mutation almost invariably show classical AME with
severe hypokalemia, hypertension and amarkedly increased (THF+5αTHF)/THE ratio.
In milder cases with isolated hypertension the identiﬁed mutation produces only a
moderate reduction in 11βHSD2 activity.
1182 P. Ferrari / Biochimica et Biophysica Acta 1802 (2010) 1178–1187include low birth weight and failure to thrive, severe hypertension,
hypokalaemia, suppressed plasma renin activity with hypoaldoster-
onaemia, polyuria, polydipsia and nephrocalcinosis. The disease is
inherited as an autosomal recessive trait, and variousmutations in the
HSD11B2 gene have subsequently been shown to cause 11βHSD2
deﬁciency. Signs and symptoms of the syndrome can be partially or
fully reversed by treatment with the MR-antagonist spironolactone
[4,57–59] or kidney transplantation [48], evidence for the crucial role
of the renal 11βHSD2 in MR protection [26,27]. Normally plasma
cortisol levels are in the sub-micromolar range, while aldosterone
levels are sub-nanomolar; even in 11βHSD protected cells intracel-
lular levels of glucocorticoid are ∼10× those of aldosterone [60]. In
AME, deﬁcient 11βHSD2 enzyme activity further elevates intracellular
glucocorticoid levels, but crucially does not generate the levels of
NADH needed to keep the cortisol–MR complexes inactive. The
resultant MR activation produces Na+ retention, volume expansion,
hypokalaemia and suppression of plasma renin and aldosterone
secretion. Thus, the hallmark of the disease is a state of excess
mineralocorticoid activity in the absence of aldosterone, and the
abnormal urinary steroid proﬁle of an increased ratio of cortisol to
cortisone metabolites, or urinary free cortisol to cortisone.
Mutations in the HSD11B2 gene have been unequivocally shown to
be the molecular basis of the syndrome of AME [46,61–77] (Fig. 3).
Most of the known mutations are found in exons 3, 4 or 5 of the
HSD11B2 gene, with the exception of the R74G and P75,Δ1nt in exon
1 [76] and L114,Δ6nt mutant in exon 2 [73]. A few mutations were
found to leave the amino acid sequence unchanged, but potentially to
cause aberrant splicing; sequence analysis of a de novo base
transversion, 771CNG in exon 4 (V254V, TGC to TGG) creates a
canonical donor splice site [76].
Although patients with homozygous mutations from different
families show varying degrees of severity in terms of clinical and
biochemical features (Fig. 4; personal observation and refs
[46,62,64,67,69,70,73]), most patients with classic AME syndrome
have characteristic signs of severe 11βHSD2 deﬁciency (Fig. 4). In
those instances, birth weights are signiﬁcantly lower than that of their
unaffected sibs, and the patients are short, underweight and
hypertensive for their age. The in vivo activity of 11βHSD2, as
assessed by urinary excretion ratio of the cortisol (THF+5αTHF) tocortisone (THE)metabolites, is characteristically abnormal,with ratios
of 6–60, whereas the normal ratio is ∼1.0. In vitro expression studies
showed that most of the mutations described result in an 11βHSD2
proteinwith absent enzymatic activity (Fig. 4) [46,61–64,66,68,71,76].
The index case reported byWerder 35 years ago [1] was found to have
a mutation at Tyr(338) of HSD11B2 [3]. This Tyr(338)His mutation
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26 °C or in the presence of the chemical chaperones glycerol 5% and
dexamethasone at 1 μM concentration, indicating thermodynamic
instability and misfolding. Experiments with the proteasomal
inhibitors MG132 and lactacystin provided supplementary evidence
that the degradation of 11βHSD2 occurs through the proteasome
pathway [3]. Therefore, in some individuals with AME impaired
11βHSD2 protein stability rather than reduced gene expression or
loss of catalytic activity seems to be responsible for the development
of hypertension.
It has become evident that depending on the degree of loss of
enzyme activity, 11βHSD2 mutations can cause a spectrum of
hypertension ranging from a severe, life-threatening disease in early
childhood to a milder form diagnosed only in adults. Mantero et al.
described a milder form of AME, which they labelled AME type II
[72,78]. In AME type II the urinary ratio of (THF+5αTHF)/THE is
almost normal, with the main abnormality in cortisol metabolism
defective in A-ring reduction presenting as prolonged plasma half-life
of [11α-3H]-cortisol [78]. As in classic AME; molecular analysis of a
large pedigree with AME type II from Sardinia showed a C945T
mutation, resulting in the substitution of a cysteine for an arginine at
codon 279 (R279C mutation) in 11βHSD2. In vitro expression of the
mutant enzyme showed an identical Km for cortisol as the wild-type
enzyme, while the maximum velocity was reduced by approximately
35% [79]. An evenmore subtle form of AMEwas reported byWilson et
al. [70] a decade ago, where a case of a young teenager with low-renin
hypertension, but without the phenotypic features of AME was found
to be caused by a mutation in HSD11B2 producing mild deﬁciency in
11βHSD2 activity. From clinical observations and in vitro co-
transfection studies 11βHSD2 activity appears mildly impaired in
heterozygotes [64], predisposing to isolated hypertension of later
onset. Heterozygous parents of childrenwith AME have been reported
to suffer from hypertension with no other characteristic signs of AME
except from slightly raised urinary (THF+5αTHF)/THE ratios [64,68].
5.2. Licorice-induced hypertension
Licorice root has been used in Europe since prehistoric times, and
is well documented in written form from the time of the ancient
Greeks. Licorice root and extracts have been used in medical herb
products, sweeteners and mouth fresheners [80]. The active ingredi-
ent of licorice is glycyrrhizic acid, which is hydrolysed into its
aglycone glycyrrhetinic acid in vivo. Licorice products are made from
peeled and unpeeled dried root, powdered or ﬁnely cut; these
formulations have different concentrations of glycyrrhizic acid, which
can vary from trace amounts to 20% based on the extraction process.
Carbenoxolone, the hemisuccinate of glcyrrhetinic acid, was previ-
ously successfully used to treat patients with peptic ulceration [81].
Licorice possesses additional endocrine effects including glucocorti-
coid activity, antiandrogen effects, and estrogenic activity [81–83].
Patients consuming excessive quantities of licorice present with
hypertension and hypokalaemia [83–85], which may be severe
enough to cause myopathy and cardiac arrhythmias. Both renin and
aldosterone levels are suppressed [31] and exchangeable Na+ levels
are increased. The condition responds to spironolactone and is
reversible upon stopping licorice ingestion [31,86]. Glycyrrhizic and
glycyrrhetinic acids have very low afﬁnity for MR, but are very potent
competitive inhibitors of 11βHSD2 (Ki of approximately 5–10 nM)
[87]. Licorice administration to normal volunteers results in a
mineralocorticoid excess state, an increase in the urinary (THF+
5αTHF)/THE ratio, an increase in plasma cortisol half-life, and a
decrease in circulating cortisone values, indicative of inhibition of
11βHSD2 in vivo [31,88]. It is now clear that licorice induces an
acquired andmilder form of AME, causing its mineralocorticoid effects
through inhibition of 11βHSD2 rather than directly occupying and
activating MR.6. Role of 11βHSD2 in “essential” hypertension
The relationship between blood pressure, mineralocorticoid effect
and salt sensitivity is complex and any attempts to assess a possible
role of impaired 11HSD2 activity as a contributing element to
hypertension or a salt-dependent driver of blood pressure increments
have to be interpreted with caution. Excess circulating aldosterone
per se does not cause hypertension in settings of sodium depletion,
as is the case in Gitelman's syndrome [89]. This condition is caused by
loss of function mutations in the Na–Cl cotransporter of the distal
convoluted tubule [90]. It features inherited salt-loss, hypokalaemic
alkalosis and excess circulating renin and aldosterone level, but
normal blood pressure [89,91]. These ﬁndings demonstrate that the
relationship between mineralocorticoid activity and blood pressure
has to be assessed in the context of total body sodium balance.
Hypertension with hypokalaemia, metabolic alkalosis and sup-
pressed plasma renin activity deﬁnes mineralocorticoid hypertension.
Mineralocorticoid hypertension is the consequence of an overactivity
of the epithelial sodium channel of renal cells in the distal nephron
and usually occurs when the MR is activated by aldosterone. Clearly,
most patients with essential hypertension lack overt signs of
mineralocorticoid excess and do not have suppressed plasma renin
or low serum potassium. However, some hypertensive patients
demonstrate subtle biochemical changes suggestive of a mineralo-
corticoid effect contributing to hypertension such as low renin levels,
a positive correlation between blood pressure and serum Na+ levels,
or a negative correlation with potassium [92]. Because subjects with
severely impaired 11βHSD2 activity present with overt features of
mineralocorticoid hypertension, it is tempting to hypothesise that
more subtle changes in 11βHSD2 activity could contribute to
hypertension in a subset of essential hypertensive patients with low
renin hypertension.
7. 11βHSD2 activity in “essential” hypertension
As described previously, in vivo 11βHSD2 activity can be assessed
by measuring the ratio of active to inactive glucocorticoids in the
urine; an increase in urinary free F/E or (THF+5αTHF)/THE ratio
indicates decreased 11βHSD2 activity [31], similarly a prolonged half-
life of plasma cortisol demonstrates reduced oxidation of cortisol to
cortisone. Some studies have reported that the half-life of cortisol is
signiﬁcantly prolonged, the excretion of urinary cortisol metabolites
increased and the vasoconstrictor response to glucocorticoids en-
hanced in some patients with essential hypertension [93,94]. In the
“4 corner study” impaired conversion of cortisol to inactive metabo-
lites has also been reported in young men with higher blood pressure
whose parents also had high blood pressure [95], and another study
found a positive association between urinary free cortisol and salt-
resistant hypertension [79]. It has also been demonstrated that age
signiﬁcantly and positively correlates with the ratios of (THF+
5αTHF)/THE and F/E, suggesting that reduced 11βHSD2 activity may
be a previously unrecognized risk factor contributing to the rising
prevalence of arterial hypertension in elderly [96]. This observation is
corroborated by the report of 11βHSD2 impairment in Japanese
elderly patients with mineralocorticoid excess state [97]. Moreover,
an impaired 11βHSD2 activity can predispose to hypertension
induced by exogenous glucocorticoids, as shown by Olivieri et al.
[98]. These authors showed that a urinary (THF+5αTHF)/THE ratio
N1.5 was associated with a 3.8-fold incremental risk of hypertension
after prednisolone therapy, regardless of duration and intensity of
exogenous corticosteroid therapy [98]. Thus, taken together, these
studies support the view that an impaired 11βHSD2 activity may play
some role in a subset of patients with essential hypertension.
Nevertheless, other authors could not conﬁrm these observations
[99,100]. There are several possible explanations for this discrepancy,
notably the differences in the ethnic groups, age, selection criteria and
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some but not all studies, of an apparent reduction in 11βHSD2 activity
in hypertensive subjects gives rise to many questions. Firstly, is this
correlative association of pathogenetic value or not? Secondly, if
indeed mildly impaired 11βHSD2 activity plays a pathogenetic role,
what degree of 11βHSD2 impairment is necessary to induce
hypertension? Thirdly, what causes impaired 11βHSD2 activity in
these subjects? Unfortunately, there are no unequivocal answers to
these questions. Furthermore, because salt plays a permissive role, it is
difﬁcult to establish whether there is a linear relationship between
11βHSD2 activity and blood pressure.
Since steroid hormones modulate renal Na+ retention, it is
possible that variations in 11βHSD2 activity may be responsible for
the sensitivity of blood pressure to changes in dietary salt intake. A
salt-sensitive response of blood pressure has been observed in not
only patients with hypertension, but also in some young normoten-
sive individuals [101]. These subjects also display a number of traits,
including suppression of the renin-angiotensin system, that can also
be found in some patients with essential hypertension [102]; it has
therefore been suggested that salt-sensitive individuals may be
genetically predisposed to the development of hypertension [103].
Our own data suggest that impaired 11βHSD2 activity is associated
with an increased susceptibility of blood pressure to salt load [104], an
observation in line with the well-established concept that low-renin
hypertension is generally considered a salt-sensitive form of high
blood pressure [103]. These ﬁndings are in apparent contrast with the
observation of Litchﬁeld et al. [79], that subjects with highest urinary
free cortisol show the least sensitivity of blood pressure to dietary
salt. In this study urinary free cortisol (but not cortisone or (THF+
5αTHF)/THE ratios) were measured, thereby not allowing a direct
evaluation of 11βHSD2 activity; reduced 11βHSD2 activity correlates
with a decrease urinary excretion of free cortisone rather than an
increased urinary free cortisol excretion [29]. Thus, measuring
cortisone and its metabolites or (THF+5αTHF)/THE in the urine
seems to be the most appropriate assay of renal 11βHSD2 activity.
Unfortunately, adequate measurements of urinary cortisol and
cortisone metabolites are not readily available and thus unsuitable
for routine screening. Other observations on the metabolism of GC
hormones seem to link 11βHSD2 function to hypertension. Low-birth
weight and/or stillbirth [67] are often found in patients with AME. It
seems likely that 11βHSD2 protects the foetus against excessive levels
of maternal glucocorticoids [105,106]; deﬁcient foetal (placental)
11βHSD2 would allow increased levels of glucocorticoids to cross the
placenta and thus inhibit foetal growth. In humans, low birth weight
is a risk factor for the development of essential hypertension in adult
life [107–109]; some clinical and experimental observations suggest
that decreased activity of placental 11βHSD2 reduces birth weight
and produces hypertensive adult offspring [49,108,109]. A mild form
of 11βHSD2 deﬁciency could therefore present as a low birth weight
infant with the onset of hypertension in later life.
7.1. 11βHSD2 gene in “essential” hypertension
It is plausible that mutations leading to decreased 11βHSD2
activity can masquerade as essential hypertension and therefore that
a subset of patients among the essential hypertensive population may
suffer from a subtle form of AME. Non-conservative mutations in the
HSD11B2 gene may not necessarily result in severely impaired
11βHSD2 activity presenting with overt AME [70]. Wilson et al
reported on a girl with a homozygous HSD11B2 gene mutation
resulting in hypertension and suppressed plasma renin levels, but no
signiﬁcant hypokalaemia or the other phenotypic features that could
support the diagnosis of AME [70]. Li et al. [68] reported that
heterozygous parents of a child with AME have hypertension and
increased urinary (THF+5αTHF)/THE ratio, but no other overt
features of AME. Generally though, the phenotypic effects of themajority of mutations in the HSD11B2 coding region in AME are quite
striking. Thus, if an inherited abnormality in 11βHSD2 is to play a role
in some patients with hypertension it is more likely that this may be
due to reduced expression of the gene, rather than expression of an
enzyme with altered amino acid sequence.
There have been few attempts to analyse whether an association
exists between HSD11B2 gene mutations, 11βHSD2 activity and
essential hypertension. The ﬁrst attempt by Watson et al. [110] was
rather circumstantial. These authors reported a genetic association of
a HSD11B2 ﬂanking microsatellite and hypertension in African-
Americans with ESKD [110]. They argued that because one of the
leading causes of ESKD in African-Americans is low-renin hyperten-
sion it is conceivable that impaired 11βHSD2 activity might be more
prevalent among this population. An association between the same
Glu178/Glu (G534A) polymorphic marker in exon 3 of HSD11B2 and
ESKD in Caucasians was also described, although this marker is not
associated with essential hypertension in humans [111]. Since this
mutation does not alter the amino acid sequence, and thus the activity
of 11βHSD2, the mechanisms underlying the association of ESKDwith
this polymorphic marker are unclear.
Structural analysis of the HSD11B2 gene in patients with ESKD
demonstrated that the frequency of homozygosity for mutated alleles
of the gene is b1/250,000 in Caucasians [112]. Others have also failed
to demonstrate the presence of mutations in the HSD11B2 coding
region and hypertension in an unselected hypertensive population.
Kamide at al. [113] sequenced the entire coding region and the
promoter region of HDS11B2 in 953 Japanese hypertensive patients
and identiﬁed a series of genetic variations in HDS11B2. They found 5
missense mutations in 11 patients and 1 novel frameshift mutation in
a heterozygous state, in addition to 19 genetic variations. All genetic
variations identiﬁedwere rare, withminor allele frequencies less than
0.005. Four missense mutations, L14F, R74H, R147H, and R335H, were
identiﬁed in hypertensive and normotensive subjects with a similar
frequency, suggesting that these missense mutations may not
strongly affect the etiology of essential hypertension [113]. These
results indicate that missense mutations in HSD11B2 do not
substantially contribute to essential hypertension in Japanese.
Brand et al. [114] analysed a polymorphic CA-repeat microsatellite
marker near the HSD11B2 gene in a large series of families with
essential hypertension, but found no correlation between this marker
and bloodpressure in their cohort.We analysed the samepolymorphic
marker in salt-sensitive subjects and found a positive association
between the short allele A7 homozygosity and salt-sensitivity, and a
negative correlation with allele pair A7/A8 of the microsatellite
marker [104], ﬁndings later conﬁrmed by Agarwal et al. [115]. This
suggests that the activity of the 11βHSD2 enzyme may be genetically
determined by variants in theHSD11B2promoter or by the presence of
undetected mutations in the HSD11B2 gene itself, an issue deserving
further investigation. These genetic ﬁndings on HSD11B2 polymorph-
isms suggesting that abnormal regulation of the gene may promote
hypertension are backed by the observation that salt-sensitive
subjects show higher cortisol levels after mental stress [116]. The
apparently divergent ﬁndings of some of these studies may be
explained by the lack of selection for the blood pressure response to
salt-load in the patients studied by Brand et al. [114].
Two different polymorphisms of the HSD11B2 gene, Thr156/Thr
(C468A) in exon 2 (ex2) and Glu178/Glu (G534A) in exon 3 (ex3),
have been shown to be signiﬁcantly more prevalent in hypertensive
subjects than in control subjects [117]. The role of these polymorph-
isms has not been further investigated, but it has been proposed that
they may be related to mutations in the promoter region of HSD11B2
or to the modulation of 11βHSD2 mRNA processing in hypertensive
subjects. This view could be supported by the observation by Agalou
et al. [118] that circulating mRNA levels for 11βHSD2 are signiﬁcantly
lower in hypertensive patients than in healthy subjects, suggesting
that measurement of mRNA for 11βHSD2 in hypertension may
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relation to hypertension is more likely to occur at the level of
HSD11B2 epigenetic control. Friso et al. [119] found that elevated
HSD11B2 promoter methylation is associated with hypertension
developing in glucocorticoid-treated patients in parallel with a higher
urinary (THF+5αTHF)/THE ratio. They also showed an association
between elevated urinary (THF+5αTHF)/THE ratio and HSD11B2
promoter methylation in essential hypertensive patients, suggesting
that there is a link between the epigenetic regulation through
repression of HSD11B2 and hypertension [119]. Future prospective
studies comparing carriers of these genetic variants compared to
wild-type subjects and looking at their blood pressure sensitivity to
salt load or licorice exposure may help clarify the pathogenetic role
11βHSD2 in essential hypertension.
8. Concluding remarks
The discovery that the juvenile hypertensive disorder called
apparent mineralocorticoid excess has unmasked a new biological
principle, in which hormone action in target organs is mediated by
enzyme and not receptor speciﬁcity. Mutations or inhibition of
11βHSD2 have clearly been shown to produce a congenital or
acquired syndrome of mineralocorticoid excess, but both are
altogether rare occurrences. Some circumstantial evidence points to
a possible role of 11βHSD2 as a mediator of increased blood pressure
in humans. However, whether and to what extent subtle abnormal-
ities in MR/11βHSD2 mechanisms may contribute to essential
hypertension is still unresolved.
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